NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
May 16 03:39PM ET
1.35
Dollar change
+0.12
Percentage change
9.76
%
Index- P/E- EPS (ttm)-3.08 Insider Own1.56% Shs Outstand6.80M Perf Week19.21%
Market Cap9.01M Forward P/E- EPS next Y-1.35 Insider Trans0.00% Shs Float6.57M Perf Month35.61%
Income-16.49M PEG- EPS next Q-0.51 Inst Own7.59% Short Float3.67% Perf Quarter-12.73%
Sales8.51M P/S1.06 EPS this Y30.97% Inst Trans-25.65% Short Ratio0.65 Perf Half Y-31.12%
Book/sh-0.21 P/B- EPS next Y32.33% ROA-36.24% Short Interest0.24M Perf Year-80.33%
Cash/sh2.29 P/C0.59 EPS next 5Y44.28% ROE-310.98% 52W Range0.95 - 9.00 Perf YTD-27.81%
Dividend Est.- P/FCF- EPS past 5Y16.27% ROI-3560.48% 52W High-84.99% Beta1.59
Dividend TTM- Quick Ratio0.92 Sales past 5Y79.05% Gross Margin39.06% 52W Low42.11% ATR (14)0.08
Dividend Ex-Date- Current Ratio1.09 EPS Y/Y TTM42.10% Oper. Margin-254.80% RSI (14)66.91 Volatility6.28% 7.80%
Employees117 Debt/Eq- Sales Y/Y TTM50.90% Profit Margin-193.69% Recom1.00 Target Price5.50
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q104.81% Payout- Rel Volume0.28 Prev Close1.23
Sales Surprise-55.56% EPS Surprise108.28% Sales Q/Q178.72% EarningsMay 21 BMO Avg Volume373.89K Price1.35
SMA2015.72% SMA5010.47% SMA200-33.15% Trades Volume99,923 Change9.76%
Date Action Analyst Rating Change Price Target Change
Oct-08-21Initiated ROTH Capital Buy $7
Jul-29-21Initiated Aegis Capital Buy $10
Dec-01-20Initiated Cantor Fitzgerald Overweight $9
Dec-16-13Initiated Oppenheimer Outperform $26
May-14-25 08:37PM
May-08-25 07:00AM
Apr-22-25 09:24AM
Apr-21-25 07:00AM
Mar-06-25 07:15AM
07:00AM Loading…
07:00AM
Feb-20-25 07:00AM
Feb-13-25 08:00AM
Nov-21-24 07:30AM
Nov-19-24 07:00AM
Nov-12-24 07:00AM
Nov-07-24 07:00AM
Oct-31-24 08:00AM
Oct-29-24 08:00AM
Oct-08-24 07:00AM
07:00AM Loading…
Sep-30-24 07:00AM
Aug-23-24 08:55AM
Aug-22-24 07:00AM
Aug-12-24 07:11AM
07:00AM
Jul-31-24 07:00AM
Jul-23-24 08:48AM
Jul-17-24 08:00AM
Jul-02-24 07:00AM
Jun-25-24 07:00AM
May-30-24 08:02AM
May-23-24 11:52AM
11:00AM
07:00AM
May-21-24 07:03AM
07:00AM Loading…
May-09-24 07:00AM
Apr-16-24 07:00AM
Apr-11-24 07:00AM
Apr-02-24 07:00AM
Mar-28-24 09:00AM
Mar-20-24 09:00AM
Mar-19-24 09:00AM
Mar-13-24 09:00AM
Mar-07-24 12:53PM
09:20AM
07:00AM
Mar-06-24 07:00AM
Mar-05-24 07:00AM
Feb-28-24 07:00AM
Feb-26-24 07:00AM
Feb-22-24 07:00AM
Feb-21-24 07:00AM
Feb-20-24 07:00AM
Feb-06-24 07:08AM
Jan-23-24 07:00AM
Jan-17-24 07:00AM
Jan-12-24 12:00PM
Dec-21-23 07:00AM
Dec-19-23 07:00AM
Dec-05-23 07:00AM
Nov-28-23 07:00AM
Nov-16-23 09:57AM
Nov-15-23 07:00AM
Nov-08-23 07:00AM
Nov-02-23 07:00AM
Oct-31-23 07:00AM
Oct-18-23 07:00AM
Sep-27-23 07:00AM
Aug-17-23 07:00AM
Aug-15-23 07:00AM
Aug-01-23 07:00AM
Jul-25-23 07:00AM
Jul-19-23 07:00AM
Jul-17-23 08:15AM
07:30AM
Jul-12-23 07:00AM
Jul-03-23 07:00AM
Jun-22-23 05:50PM
Jun-21-23 07:00AM
May-24-23 07:00AM
May-18-23 07:00AM
May-09-23 07:00AM
May-04-23 07:00AM
May-02-23 07:00AM
Apr-28-23 09:00AM
Apr-27-23 07:00AM
Mar-30-23 04:01PM
Mar-29-23 07:00AM
Mar-21-23 01:45PM
Mar-15-23 08:00AM
Mar-13-23 01:56AM
Mar-09-23 07:00AM
Mar-06-23 07:00AM
06:55AM
Mar-01-23 04:01PM
07:00AM
Feb-28-23 07:00AM
Feb-27-23 08:00AM
Feb-21-23 07:00AM
Jan-24-23 07:00AM
Jan-19-23 07:00AM
Dec-28-22 07:00AM
Dec-21-22 06:00AM
Dec-08-22 07:00AM
Nov-17-22 08:25AM
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.